Editor's note: Recently, Angkai Life Technology (Suzhou) Co., Ltd. (referred to as "Angkai Life") announced that it has received the first round of financing of more than 10 million yuan. This round was jointly invested by Guoqian Fund and Huatai Zijin.
Angkai Life is an innovative enterprise focusing on the development and application of early tumor liquid detection technology. After years of technical accumulation and exploration, Angkai Life's core team independently developed DNA methylation hypersensitivity joint detection technology (MeMore). This technology was developed for the detection of the methylation status of trace DNA, and it has the advantages of ultra-sensitivity, high precision, low cost, and simplicity. This technology greatly improves the accuracy of early screening of tumors, while subversively reducing the cost of detection, effectively breaking the bottleneck of DNA methylation detection technology, reconstructing clinical application scenarios, and will promote pan-cancer early screening into the field of general screening and improve tumor Patient survival time and quality reduce the cost of comprehensive tumor treatment. Angkai Life focuses on the development of cost-effective cancer early screening solutions and products, and is committed to let high-tech gene technology benefit the public.
Ang Kai Life Scientist: Dr. Wang Qianghu
Dr. Wang Qianghu, a life scientist at Angkai, said that with the increasing living standards of the people, the demand for health management and prevention of major diseases is becoming more and more urgent. Cancer screening techniques and physical examinations have attracted widespread attention, and China has also included “early diagnosis and early treatment of cancer” as a strategy for healthy China. Angkai Life is committed to developing low-cost, high-throughput, high-accessibility blood free DNA methylation detection technology and products. We are deeply honored that the team and technology of Angkai Life can be recognized and favored by Guoqian Venture Capital and Huatai Zijin. The successful financing will greatly promote Angkai Life's rapid development in product layout, research and development, team and other aspects. The investor's entire industrial chain ecological layout in the field of medical devices has made us benefit a lot. Angkai Life will use this as a starting point, as always, carry out scientific, rigorous and efficient research and development of early cancer screening products, and contribute to the realization of "Healthy China" as soon as possible.
Ang Kai Life CEO: Dr. Zhao Hui
Dr. Zhao Hui, CEO of Angkai Life, said that his many years of experience in the hospital's cancer center made him deeply appreciate the despair and helplessness of cancer patients at the moment of diagnosis of the tumor. People's fear of cancer discoloration stems from the phenomenon that many cancers are found at an advanced stage. The treatment cost of advanced tumors is high and the recovery is poor, so early detection of tumors is extremely important. With the mission of promoting gene technology to benefit the public, Angkai Life has independently developed MeMore technology to enable early cancer screening. Thanks to Dr. Zhang Xu, the chairman of Guoqian Venture Capital, and the team's recognition of MeMore technology, and to Huatai Zijin's blessing. The help of capital will quickly promote the extension of the clinical application of MeMore technology, break the curse of cancer discovery and late stage, and create value for society.
Chairman of Guoqian Venture Capital: Dr. Zhang Xu
Dr. Zhang Xu, Chairman of Guoqian Venture Capital, said that the global tumor liquid biopsy market is developing rapidly. The unique technical platform "MeMore" of the Angkai team is mainly for the detection of plasma free DNA methylation, which can be applied to the early screening and joint screening of various tumors. A good balance is achieved, and it is expected to become a benchmark pan-cancer early screening technology in the future. We look forward to the era of Angkai team belonging to "innovators" and "focusers".
General Manager of Huatai Zijin: Ms. Cao Qun
Ms. Cao Qun, general manager of Huatai Zijin, said that Angkai Life has deep technical reserves in tumor genomics, molecular diagnosis and bioinformatics. The self-developed DNA methylation hypersensitivity joint detection technology is expected to quickly screen for pan cancer early And diagnostic applications. We are honored to support such a team of scientists and entrepreneurs as Angkai Life, and look forward to their industrialization of more scientific research results to meet the urgent needs of clinical tumor diagnosis.
Guoqian Venture Capital Management (Suzhou) Co., Ltd.
Based on the business philosophy of “achieving the dreams of others”, Guoqian Venture Capital seeks high-quality investment targets in the process of talent project introduction, innovation and entrepreneurship project evaluation, and transformation of scientific and technological achievements by special experts from the Central Organization Department. Specially hired expert resources to provide professional guidance and resource integration in technology, industry, policy, clinical, industrialization, etc. At the same time, through talent project introduction and service, entrepreneurship project innovation incubation and acceleration, holding high-end industrial forums, industrial investment and integration and other businesses Create an innovative technology investment and industrial integration platform with national characteristics. Guoqian Venture Capital has so far invested in Aishi Medical (Ophthalmology AI), Ruiqian Medical (Pathology AI), Xinqing Medical (in vitro artificial heart), Spectrum Life (mass spectrometry detection), Huanuo Biological (hemostatic material), Qing Spectral technology (small-scale mass spectrometry), Guoke Junhao (POCT), Bicode (monoclonal antibody protein) and many other start-up high-quality enterprises. At the same time, Guoqian Venture Capital and its parent company Guoqian Medical strive to build a medical device in China through 8-10 years through the introduction and service of talent projects, innovation incubation and acceleration of entrepreneurial projects, industrial investment and integration, etc. Industrial clusters and ecosystems have become one of the main promoters of the domestic medical device industry.